{"analyses":[{"ciLowerLimit":"0.87","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.18","groupIds":["OG000","OG001"],"nonInferiorityComment":"To detect a hazard ratio (HR) of 0.80 between exemestane and anastrozole (ie, an improvement in 5-year EFS from 87.5% to 89.9%, with a two-sided 5% level test and 80% power, 6,840 patients and 630 events were needed for final analysis.","nonInferiorityType":"SUPERIORITY","pValue":"0.85","paramType":"Hazard Ratio (HR)","paramValue":"1.02","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"87","upperLimit":"89","value":"88"},{"groupId":"OG001","lowerLimit":"88","upperLimit":"90","value":"89"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3789"},{"groupId":"OG001","value":"3787"}],"units":"Participants"}],"description":"Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral exemestane (25 mg) once daily for 5 years.\n\nexemestane: Given orally","id":"OG000","title":"Exemestane"},{"description":"Patients receive oral anastrozole (1 mg) once daily for 5 years.\n\nanastrozole: Given orally","id":"OG001","title":"Anastrozole"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"5 years","title":"Event-free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}